Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients

M. Valle; K. Van Der Speeten; A. Garofalo

doi:10.1002/jso.21321

Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients

M. Valle, K. Van Der Speeten, A. Garofalo

Istituto Regina Elena

Research output: Contribution to journal › Article › peer-review

Abstract

Malignant ascites is a debilitating condition affecting cancer patients in their terminal stage of disease. Recently, laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) was introduced as a new approach. From September 2001 to August 2008, 52 patients were treated with this new modality. No treatment-related mortality was observed. Median survival was 98 days. One patient developed a clinical recurrence. Laparoscopic HIPEC is a safe and effective method for palliating malignant ascites.

Original language	English
Pages (from-to)	331-334
Number of pages	4
Journal	Journal of Surgical Oncology
Volume	100
Issue number	4
DOIs	https://doi.org/10.1002/jso.21321
Publication status	Published - Sep 15 2009

Keywords

Chemotherapy
Intraperitoneal
Laparoscopy
Malignant ascites

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1002/jso.21321

Cite this

Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites : A multi-institutional retrospective analysis in 52 patients. / Valle, M.; Van Der Speeten, K.; Garofalo, A.

In: Journal of Surgical Oncology, Vol. 100, No. 4, 15.09.2009, p. 331-334.

Research output: Contribution to journal › Article › peer-review

@article{45dbf12696de4bc9807f1cbcb07cabf9,

title = "Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients",

abstract = "Malignant ascites is a debilitating condition affecting cancer patients in their terminal stage of disease. Recently, laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) was introduced as a new approach. From September 2001 to August 2008, 52 patients were treated with this new modality. No treatment-related mortality was observed. Median survival was 98 days. One patient developed a clinical recurrence. Laparoscopic HIPEC is a safe and effective method for palliating malignant ascites.",

keywords = "Chemotherapy, Intraperitoneal, Laparoscopy, Malignant ascites",

author = "M. Valle and {Van Der Speeten}, K. and A. Garofalo",

year = "2009",

month = sep,

day = "15",

doi = "10.1002/jso.21321",

language = "English",

volume = "100",

pages = "331--334",

journal = "Journal of Surgical Oncology",

issn = "0022-4790",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites

T2 - A multi-institutional retrospective analysis in 52 patients

AU - Valle, M.

AU - Van Der Speeten, K.

AU - Garofalo, A.

PY - 2009/9/15

Y1 - 2009/9/15

N2 - Malignant ascites is a debilitating condition affecting cancer patients in their terminal stage of disease. Recently, laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) was introduced as a new approach. From September 2001 to August 2008, 52 patients were treated with this new modality. No treatment-related mortality was observed. Median survival was 98 days. One patient developed a clinical recurrence. Laparoscopic HIPEC is a safe and effective method for palliating malignant ascites.

AB - Malignant ascites is a debilitating condition affecting cancer patients in their terminal stage of disease. Recently, laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) was introduced as a new approach. From September 2001 to August 2008, 52 patients were treated with this new modality. No treatment-related mortality was observed. Median survival was 98 days. One patient developed a clinical recurrence. Laparoscopic HIPEC is a safe and effective method for palliating malignant ascites.

KW - Chemotherapy

KW - Intraperitoneal

KW - Laparoscopy

KW - Malignant ascites

UR - http://www.scopus.com/inward/record.url?scp=69749109618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69749109618&partnerID=8YFLogxK

U2 - 10.1002/jso.21321

DO - 10.1002/jso.21321

M3 - Article

C2 - 19697441

AN - SCOPUS:69749109618

VL - 100

SP - 331

EP - 334

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 4

ER -

Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this